RARE Research and Charts

RARE - Ultragenyx Pharmaceutical Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-04 (Delayed quote data 2025-01-06)

Last 42.66	Change ⇑ +1.16 (+2.80%)	Volume 1,908,186
	Open 41.51	High 42.93	Low 41.06

8EMA (Daily) 42.59	40EMA (Daily) 46.13	50EMA (Daily) 46.86	STO (Daily) 18.236	MACD Hist (Daily) -0.197
8EMA (Weekly) 44.972	40EMA (Weekly) 47.57	50EMA (Weekly) 47.36	STO (Weekly) 12.768	MACD Hist (Weekly) -2.471


Company Profile
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.